BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 21605729)

  • 1. Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies.
    Yu EW; Bauer SR; Bain PA; Bauer DC
    Am J Med; 2011 Jun; 124(6):519-26. PubMed ID: 21605729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing proton pump inhibitors with histamin-2 receptor blockers regarding the risk of osteoporotic fractures: a nested case-control study of more than 350,000 Korean patients with GERD and peptic ulcer disease.
    Park JH; Lee J; Yu SY; Jung JH; Han K; Kim DH; Rhee J
    BMC Geriatr; 2020 Oct; 20(1):407. PubMed ID: 33059626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proton Pump Inhibitors, Histamine-2 Receptor Antagonists, and Hip Fracture Risk among Patients on Hemodialysis.
    Vangala C; Niu J; Lenihan CR; Mitch WE; Navaneethan SD; Winkelmayer WC
    Clin J Am Soc Nephrol; 2018 Oct; 13(10):1534-1541. PubMed ID: 30262672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients.
    Corley DA; Kubo A; Zhao W; Quesenberry C
    Gastroenterology; 2010 Jul; 139(1):93-101. PubMed ID: 20353792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study of the association between hip fracture and acid-suppressive drug use in a UK primary care setting.
    Cea Soriano L; Ruigómez A; Johansson S; García Rodríguez LA
    Pharmacotherapy; 2014 Jun; 34(6):570-81. PubMed ID: 24634193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proton-pump inhibitors and risk of fractures: an update meta-analysis.
    Zhou B; Huang Y; Li H; Sun W; Liu J
    Osteoporos Int; 2016 Jan; 27(1):339-47. PubMed ID: 26462494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acid-suppressive medications and risk of bone loss and fracture in older adults.
    Yu EW; Blackwell T; Ensrud KE; Hillier TA; Lane NE; Orwoll E; Bauer DC
    Calcif Tissue Int; 2008 Oct; 83(4):251-9. PubMed ID: 18813868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term proton pump inhibitor therapy and risk of hip fracture.
    Yang YX; Lewis JD; Epstein S; Metz DC
    JAMA; 2006 Dec; 296(24):2947-53. PubMed ID: 17190895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of proton pump inhibitors is associated with fractures in young adults: a population-based study.
    Freedberg DE; Haynes K; Denburg MR; Zemel BS; Leonard MB; Abrams JA; Yang YX
    Osteoporos Int; 2015 Oct; 26(10):2501-7. PubMed ID: 25986385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies.
    Poly TN; Islam MM; Yang HC; Wu CC; Li YJ
    Osteoporos Int; 2019 Jan; 30(1):103-114. PubMed ID: 30539272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative analysis of the risk of osteoporotic fractures with proton pump inhibitor use and histamine-2 receptor antagonist therapy in elderly women: A nationwide population-based nested case-control study.
    Park JH; Song YM; Jung JH; Han K
    Bone; 2020 Jun; 135():115306. PubMed ID: 32126312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Associations between Proton Pump Inhibitor and Histamine-2 Receptor Antagonist and Bone Mineral Density among Kidney Transplant Recipients.
    Lyu B; Hansen KE; Jorgenson MR; Astor BC
    Am J Nephrol; 2020; 51(6):433-441. PubMed ID: 32485707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proton pump inhibitors: bacterial pneumonia.
    Prescrire Int; 2012 Sep; 21(130):210-2. PubMed ID: 23016253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of acid-suppressive drugs and risk of fracture in children and young adults: a meta-analysis of observational studies.
    Yang J; Zhou TJ; Yang J; Bao DN
    Eur J Clin Pharmacol; 2022 Mar; 78(3):365-373. PubMed ID: 34705066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of acid-suppressive drugs and risk of fracture: a meta-analysis of observational studies.
    Eom CS; Park SM; Myung SK; Yun JM; Ahn JS
    Ann Fam Med; 2011; 9(3):257-67. PubMed ID: 21555754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of post-stroke pneumonia with proton pump inhibitors, H2 receptor antagonists and mucoprotective agents: A retrospective nationwide cohort study.
    Song TJ; Kim J
    PLoS One; 2019; 14(5):e0216750. PubMed ID: 31067267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study.
    Pouwels S; Lalmohamed A; Souverein P; Cooper C; Veldt BJ; Leufkens HG; de Boer A; van Staa T; de Vries F
    Osteoporos Int; 2011 Mar; 22(3):903-10. PubMed ID: 20585937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-analysis: risk of fractures with acid-suppressing medication.
    Kwok CS; Yeong JK; Loke YK
    Bone; 2011 Apr; 48(4):768-76. PubMed ID: 21185417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proton pump inhibitor use and the risk of osteoporosis and fracture in stroke patients: a population-based cohort study.
    Lin SM; Yang SH; Liang CC; Huang HK
    Osteoporos Int; 2018 Jan; 29(1):153-162. PubMed ID: 29032384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between proton pump inhibitors use and risk of hip fracture: A general population-based cohort study.
    Wei J; Chan AT; Zeng C; Bai X; Lu N; Lei G; Zhang Y
    Bone; 2020 Oct; 139():115502. PubMed ID: 32593677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.